Tiziana Life Sciences PLC

("Tiziana" or the "Company")

 

Grant of options - Director's dealing

 

London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that the Remuneration Committee proposed and the Board has awarded the following options on 30 August 2017.

 

Dr Kunwar Shailubhai, the Company's Chief Executive Officer and Chief Scientific Officer, has been awarded options over 400,000 ordinary shares in the capital of the Company.  The options are exercisable at a price of 159.5 pence per share.  The options will vest in equal tranches over four years beginning on the date of grant. Dr Shailubhai already holds 300,000 options at an exercise price of 50p pursuant to an award made on 25 June 2014 (of which 200,000 options are vested and 100,000 remain subject to vesting conditions).

 

A further 168,000 options over ordinary shares in the capital of the Company were granted by the Company to staff members on the same terms and on the same date.

 

The Company's issued share capital comprises 123,827,938 ordinary shares of 3p each.

 

Including the grants noted above, the Company has granted options over a total of 10,717,403 ordinary shares of which 4,752,500 are vested at exercise prices between 15p and £1.25p per share and 5,964,903 remain subject to vesting conditions (at potential exercise prices ranging from 15p to £1.925 per share). In addition warrants to subscribe for a total of 4,239,579 ordinary shares at exercise prices between 50p and £2.50 are outstanding.

 

Therefore the fully diluted issued share capital of the Company is 138,784,920 ordinary shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Contacts:

 

Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder	+44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner / Richard Nash	+44 (0)20 7213 0880
Beaufort Securities Limited (Broker) Saif Janjua	+44 (0)20 7382 8300
FTI Consulting Simon Conway / Natalie Garland-Collins	+44 (0)20 3727 1000

 

About Tiziana Life Sciences

 

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For more information go to http://www.tizianalifesciences.com 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr Kunwar Shailubhai
2	Reason for notification
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	31 August 2017
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Tiziana Life Sciences plc
b.	LEI
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument   Identification Code	Option   GB00BKWNZY55
b.	Nature of the transaction	Grant of options
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			159.5p	400,000
d.	Aggregated information   - Aggregated Volume   - Price	400,000   159.5p
e.	Date of the transaction	31 August 2017
f.	Place of the transaction	XLON